Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
20.01B
Market cap20.01B
Price-Earnings ratio
7.90
Price-Earnings ratio7.90
Dividend yield
—
Dividend yield—
Average volume
2.91M
Average volume2.91M
High today
$157.18
High today$157.18
Low today
$147.58
Low today$147.58
Open price
$155.01
Open price$155.01
Volume
2.52M
Volume2.52M
52 Week high
$479.79
52 Week high$479.79
52 Week low
$147.58
52 Week low$147.58

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $149.95. The company's market cap stands at 20.01B, with a P/E ratio of 7.90.

As of 2026-11-18, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $147.58 and $157.18. The current price stands at $149.95, placing the stock +1.6% above today's low and -4.6% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 2.52M, compared to an average daily volume of 2.91M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $479.79 and a 52-week low of $147.58.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $479.79 and a 52-week low of $147.58.

ALNY News

Investing.com 7h
Alnylam Pharmaceuticals stock hits 52-week low at 149.17 USD - Investing.com

...

Alnylam Pharmaceuticals stock hits 52-week low at 149.17 USD - Investing.com
TipRanks 15h
Alnylam price target lowered to $254 from $369 at JPMorgan

JPMorgan lowered the firm’s price target on Alnylam (ALNY) to $254 from $369 and keeps an Overweight rating on the shares. The firm attributes the stock’s 61% s...

Simply Wall St 3d
Is Alnylam Pharmaceuticals Undervalued On Strong New AMVUTTRA Data?

Alnylam Pharmaceuticals (ALNY) has become a focus for many investors after new five-year AMVUTTRA data presented at the American Heart Association Scientific Se...

Is Alnylam Pharmaceuticals Undervalued On Strong New AMVUTTRA Data?

Analyst ratings

63%

of 30 ratings
Buy
63.3%
Hold
36.7%
Sell
0%

More ALNY News

Simply Wall St 7d
Alnylam Pharmaceuticals Is Up 5.4% What’s Changed After Five Year Drug Data

Alnylam Pharmaceuticals reported new five year HELIOS-B data showing continuous AMVUTTRA treatment was associated with lower all-cause mortality and recurrent c...

Alnylam Pharmaceuticals Is Up 5.4% What’s Changed After Five Year Drug Data

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.